EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEL STUDY

Edward V. Loftus  ¹     Jean-Frédéric Colombel  ²     Ana Paula Lacerda  ³     Laurent Peyrin-Biroulet  ⁴     Geert R. D'Haens  ⁵     Remo Panaccione  ⁶     Walter Reinisch  ⁷     Edouard Louis  ⁸     Minhu Chen  ⁹     Hiroshi Nakase  ¹⁰     Susan Greenbloom  ¹¹     Aaron Duvall  ¹²     Yuri Sanchez Gonzalez  ³     Mohamed-Eslam F. Mohamed  ³     Susan Rhee  ³     Tian Feng  ³     Elena Dubcenco  ³     Julian Panés  ^13    
1 Mayo Clinic College of Medicine and Science, Rochester, United States
² Icahn School of Medicine at Mount Sinai, New York City, United States
³ AbbVie, North Chicago, United States
⁴ University Hospital of Nancy, Lorraine University, Vandoeuvre, France
⁵ Amsterdam University Medical Centers, Amsterdam, Netherlands
⁶ University of Calgary, Alberta, Canada
⁷ Medical University of Vienna, Vienna, Austria
⁸ University Hospital CHU of Liège, Liege, Belgium
⁹ The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
¹⁰ Sapporo Medical University School of Medicine, Sapporo, Japan
¹¹ Toronto Digestive Disease Associates, Woodbridge, Canada
¹² Tyler Research Institute, Tyler, United States
¹³ Hospital Clinic Barcelona, Barcelona, Spain

Topic
IBD, Nurses, Primary Care

Session
Clinical trials in Crohn's disease

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)